Interleukin level in adolescent depressive disorders with and without somatic symptoms

ObjectiveTo analyze the serum interleukin level in patients with adolescent depression disorders, and analyze its correlation with somatic symptoms.

MethodsA total of 93 patients with adolescent depression disorders treated in the Hefei Fourth People's Hospital from December 2020 to December 2021 were selected and divided into functional somatic symptoms (FSS) group (n=40) and non-FSS group (n=53) according to whether they were accompanied by FSS.At the same time, thirty-two volunteers were selected as the control group.The Hamilton depression rating scale (HAMD) and childhood somatization inventory (CSI) were used to evaluate the severity of disease.The enzyme-linked immunosorbent assay was applied to detect the levels of serum IL-13 and serum IL-12/23p40.

ResultsThe level of IL-13 in FSS group was significantly higher than that of the non-FSS group and control group (P < 0.05), and there was no statistically significant difference between the non-FSS group and control group (P>0.05).The level of IL-12/23p40 in the FSS group significantly higher than that in the non-FSS group (P < 0.05), while both had no significant difference with control group (P>0.05).The level of IL-13 and IL-12/23p40 were positively correlated with CSI total score and its sub-factor scores (IL-13:r=0.360, 0.286, 0.366, 0.310, 0.336, P < 0.01;IL-12/23p40:r=0.333, 0.360, 0.275, 0.280, 0.313, P < 0.01).

ConclusionsThe level of serum IL-13 in adolescent depression patients with somatic symptoms is abnormal, and it has a positive correlation patients with somatic symptoms.